Paediatric brain tumours are the deadliest form of childhood cancer, yet most treatments are adapted from adult care and often miss the mark. A new...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 21/Aug 05:22
Study finds promising new combo therapy for drug-resistant melanoma
A new study may offer a breakthrough for patients with advanced melanoma who don’t respond to current immunotherapy treatments. The research, published in the Journal for ImmunoTherapy of Cancer, found that adding a third immune-targeting drug to existing therapies helped shrink tumours in lab models of treatment-resistant melanoma. Immunotherapy works by activating the body’s immune system to attack [...]
Articles similaires
New review calls for age-specific immunotherapy in childhood brain tumours
oncologynews.com.au - 19/Sep 16:28
Paediatric brain tumours are the deadliest form of childhood cancer, yet most treatments are adapted from adult care and often miss the mark. A new...
'Grim reaper': RFK Jr crony scorched by WSJ for attack on lifesaving cancer research
rawstory.com - 23/Sep 00:51
The Wall Street Journal editorial board slammed a key subordinate of Health and Human Services Secretary Robert F. Kennedy Jr. on Monday, calling him...
'Grim reaper': RFK Jr crony scorched by WSJ for attack on lifesaving cancer research
rawstory.com - 23/Sep 00:51
The Wall Street Journal editorial board slammed a key subordinate of Health and Human Services Secretary Robert F. Kennedy Jr. on Monday, calling him...
US FDA grants breakthrough therapy designation to Daiichi Sankyo & Merck's raludotatug deruxtecan for patients with CDH6 expressing platinum─resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab
pharmabiz.com - 16/Sep 04:28
Raludotatug deruxtecan (R─DXd) has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the...
Scientists discover powerful new antibiotic to fight superbugs
knowridge.com - 22/Sep 23:54
Scientists at the University of Liverpool, together with international collaborators, have discovered a powerful new class of antibiotics that could...
Precision targeting of the centromedian nucleus offers hope for people with drug-resistant epilepsy
news.medical.net - 16/Sep 15:32
It is estimated that one-third of the 50 million people worldwide with epilepsy are resistant to anti-seizure medications. These patients, having...
New molecule offers a more targeted and potent immunotherapy
news.medical.net - 18/Sep 04:47
A newly developed molecule brings together two powerful immunotherapy strategies in one treatment. Researchers at the University of Basel and...
Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Previously Treated with Bevacizumab
drugs.com - 15/Sep 01:09
BASKING RIDGE, N.J. AND RAHWAY, N.J., September 15, 2025 – Raludotatug deruxtecan (R-DXd) has been granted Breakthrough Therapy Designation...
Les derniers communiqués
-
Evergreen Elevate Heads to Australia to Empower MSPs with Valuable Strategies and Insights on Better M&A Practices
Evergreen Elevate - 29/07/2025